Login to Your Account

Clinic Roundup

Thursday, September 5, 2013
Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it reached enrollment of 50 percent of the patients planned in its randomized Phase III trial of Iclusig (ponatinib) in adults with newly diagnosed chronic myeloid leukemia (CML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription